This HTML5 document contains 119 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n11http://dx.doi.org/10.1016/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q45072359
rdf:type
wikibase:Item
schema:description
наукова стаття, опублікована в жовтні 2004 2004年學術文章 2004年学术文章 artikulong pang-agham tieteellinen artikkeli מאמר מדעי scientific article published in October 2004 2004年学术文章 2004年の論文 научни чланак artigo científico wissenschaftlicher Artikel artikel ilmiah 2004年学术文章 naučni članak επιστημονικό άρθρο articolo scientifico 2004年學術文章 2004年學術文章 tudományos cikk บทความทางวิทยาศาสตร์ vitskapeleg artikkel teaduslik artikkel научная статья 2004년 논문 مقالة علمية نشرت في أكتوبر 2004 2004年學術文章 artikull shkencor artykuł naukowy wetenschappelijk artikel artículo científico publicado en 2004 2004年學術文章 vědecký článek article scientific научни чланак 2004 nî lūn-bûn scientific article published in October 2004 artigo científico 2004年学术文章 artigo científico videnskabelig artikel article científic vitenskapelig artikkel vedecký článok article scientifique bài báo khoa học scientific article published in October 2004 অক্টোবর ২০০৪-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ научна статия articol științific 2004年学术文章 artículu científicu vetenskaplig artikel scienca artikolo სამეცნიერო სტატია 2004年学术文章 мақолаи илмӣ bilimsel makale
p:P577
wds:Q45072359-0D8139AE-F8A4-40CF-B49C-48C8692CACF1
wdt:P577
2004-10-01T00:00:00Z
p:P407
wds:Q45072359-2D57F549-D726-42A8-BA01-247312C706C2
wdt:P407
wd:Q1860
p:P2860
wds:Q45072359-EEF384E7-B18A-4C1F-B7D6-26265E09C1F3 wds:Q45072359-000E6238-949E-4600-9CE2-EFC0F2EA8CD6 wds:Q45072359-1D09699A-A424-46D0-BEF2-280E8925861F wds:Q45072359-5F59BF64-6838-416E-9688-176852B71A8D wds:Q45072359-7DC198F3-0956-4E2F-8474-B8A01DBF2524 wds:Q45072359-B4A86F5B-7A95-41E1-9783-E335C5C191C9 wds:Q45072359-C939B743-E702-41A4-A664-984E29BF7AD0 wds:Q45072359-E91C84D2-B234-4C40-ABEE-08F13373D391
wdt:P2860
wd:Q73443071 wd:Q77953999 wd:Q53300225 wd:Q44695865 wd:Q37649484 wd:Q73574213 wd:Q68927282 wd:Q43675453
p:P2093
wds:Q45072359-F0FE9A08-878B-4027-987B-286BC3540AAF wds:Q45072359-E9F8C234-B081-49D6-B515-D67B152B1A49 wds:Q45072359-FD817C2D-717C-40FE-8232-FD468790085B wds:Q45072359-2088FF12-C379-4595-8BBC-1CC3001CC69B wds:Q45072359-B456BED5-BBD0-499C-A1A5-F1B12ACA416A
wdt:P2093
Steven Sun Alan N Gordon Wayne Rackoff Doxil Study 30-49 Investigators Margaret Tonda
rdfs:label
Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer
skos:prefLabel
Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer
schema:name
Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer
p:P1476
wds:Q45072359-7BFCA3AF-147A-462E-8F86-38C86FF73856
wdt:P1476
Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer
p:P304
wds:Q45072359-BB0EE309-B031-4B94-990E-42D72A757921
wdt:P304
1-8
p:P31
wds:Q45072359-CE12386E-063B-413A-8AB2-C54D50F9EE9E
wdt:P31
wd:Q13442814
p:P921
wds:Q45072359-F7E7C746-4EE4-4044-BBC7-90E33B0DA2EB wds:Q45072359-4B29BD8A-D811-404C-9D3A-6C5D98162B3C
wdt:P921
wd:Q172341 wd:Q18936
p:P698
wds:Q45072359-9280D5E4-B869-44DE-BB2F-1DA3FC0B99F9
wdtn:P698
n10:15385103
wdt:P698
15385103
p:P1433
wds:Q45072359-DF0A8446-2752-4125-830F-56770603DC39
wdt:P1433
wd:Q5625182
p:P433
wds:Q45072359-1A6F23A1-7257-4135-B1EB-8A047C19B765
p:P478
wds:Q45072359-EA69F974-885F-4F5C-AC88-EB58484824AB
wdt:P433
1
wdt:P478
95
p:P356
wds:Q45072359-0D066AF7-0BE3-4FA6-98F8-AF9418DFD361
wdtn:P356
n11:J.YGYNO.2004.07.011
wdt:P356
10.1016/J.YGYNO.2004.07.011
p:P5875
wds:Q45072359-21548C53-E017-4B9A-8FB4-209F1EA7A956
wdt:P5875
8330110